Oswaldo Muñoz, pioneer of Venezuelan community in Miami, dies after long illness
Founder of the community newspaper El Venezolano and later of El Venezolano TV, both based in Miami, Muñoz was a beloved and visionary figure who helped weave the first threads of unity among Venezuelans in South Florida, back when they were just beginning to arrive in the city in the early 1990s.
He died as he lived: discreetly, surrounded by the love of those closest to him, and faithful to his nature of shielding others from his own suffering.
'He didn't want anyone to know what he was going through,' said Ignacio Marcano, one of his closest companions during his final days. 'He would tell people he was just getting some tests done. He never wanted to worry anyone.'
After Muñoz's final hospital visit, his doctors decided to sedate him. He passed away peacefully at 7 am local time in Madrid.
Pioneer in unknown territory
Oswaldo arrived in Miami in 1991, at a time when the Venezuelan community was so small that, as he liked to say, 'we could all fit in a restaurant dining room.' He founded El Venezolano in August 1992, just days after the devastating impact of Hurricane Andrew on South Florida. Against all odds, he managed to distribute the first edition amid the hurricane's devastation.
From then on, El Venezolano became a beacon for thousands of newly arrived Venezuelans seeking news, guidance and a voice to represent them in exile. What began as a modest entrepreneurial venture turned into an influential media outlet with franchises in other U.S. cities and across Latin America.
'Oswaldo was the Venezuelan who brought Venezuelans and the local Miami community together the most,' said José Hernández, a friend and colleague who led the editorial team at El Venezolano for years. 'He was one of the first visible leaders at a time when there were hardly any Venezuelans in the city. He shared spaces with figures like Jorge Mas Canosa and other important community leaders.'
More than just a paper
For years, El Venezolano served as an extension of the Venezuelan consulate, especially when the official representation ceased operating in Miami.
'On many occasions, we functioned as the consulate,' recalls Sylvia Bello, Muñoz's business partner, friend and colleague for 25 years. 'Oswaldo was a man who supported so many people in every way.'
The paper became a platform for employment, integration and gathering. 'He gave work to a lot of people,' Bello said. 'He organized events that brought together hundreds. At our anniversary editions, we hosted as many as 600 people in Miami's most prestigious hotels. Those were celebrations that showcased the strength and pride of our community.'
Between 1998 and the years leading up to the COVID-19 pandemic, El Venezolano was an undisputed reference point—not only for its content but also for the approachable and charismatic style of its founder.
Muñoz had a natural ability to connect with public figures and celebrities, his colleagues said. 'He was friends with everyone: El Puma (José Luis Rodríguez), the Stefans (Gloria and Emilio), you name it. He wasn't afraid of anything. He'd pick up the phone and everyone would answer,' Bello recalled.
Those who knew him agree that behind the editor was a deeply generous person, always ready to help. 'He was the friend everyone wants to have—unconditional, compassionate, always smiling,' Bello added.
For many immigrants arriving without support networks, without jobs, and without any idea of how to begin anew in a foreign city, Oswaldo was a guide and anchor. 'There was no one who approached him for help and didn't receive it,' Hernández said. 'In a way, he helped the city grow. Many people advertised with him, and many businesses started thanks to El Venezolano.'
In a story he proudly shared, Oswaldo recounted meeting Nobel-prize winning novelist Gabriel García Márquez at a book fair in Bogotá. The Colombian writer complimented his writing. Oswaldo humbly replied that he wasn't a journalist by profession. García Márquez responded: 'You're wrong. Journalism is a craft, not a profession.'
Few lines could have better described Muñoz's path. Without a university degree in journalism, he built a career based on vocation, instinct, empathy and an ability to connect with people.
Enduring legacy
Muñoz's legacy cannot be measured solely in printed issues or TV broadcasts. His greatest contribution, those close to him said, is the community he helped build. 'He fulfilled all his dreams,' says Sylvia Bello. 'Now he's in a better place, and he left a mark on each of us who knew him.'
Over the last three years, Oswaldo waged a tough battle with cancer. It started in his spine, then moved to his lungs. Later, doctors needed to remove a kidney. Despite everything, he managed to recover multiple times.
'He always had this amazing ability to bounce back. I don't know how he did it,' Bello says. 'But eventually, his body said, 'This is it.''
Despite his deteriorating health, he tried to maintain life as normal as possible, those close to him said.
Muñoz leaves behind a grateful community, dozens of friends, former coworkers, readers, and partners who considered him family, his friends said. He also leaves behind a body of work that will live on through the pages of El Venezolano and in the memories of those whose lives he touched.
He was, in the words of those who knew and admired him, 'the unconditional friend everyone hopes to have,' perhaps the best headline to remember his life by.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Pemphigoid or Psoriasis? 65-Year-Old's Remote Diagnosis Race
Patients with cancer often require specialised care at centres located far from their residence. During the COVID-19 pandemic, telemedicine has rapidly gained ground as a way to ease system pressures and maintain continuity of care. A 65-year-old man developed severe cutaneous toxicity, presenting as a rare bullous pemphigoid (BP) rash after 2 years on nivolumab. Notably, the reaction occurred in an outpatient setting during the COVID-19 pandemic. With coordinated support from rural providers and the use of telemedicine, his corticosteroid-refractory immune checkpoint inhibitor (ICI) toxicity was successfully managed. The case reported by Tom Marco, DO, and colleagues from the Department of Internal Medicine, University of Arizona College of Medicine, Tucson, Arizona, highlighted how remote monitoring helped diagnose and manage a rare but serious complication of cancer therapy. The Patient and His History The patient with no prior medical history presented to the emergency department with gross haematuria. A CT scan of the abdomen and pelvis revealed a large right renal mass, embracing the inferior margin of the liver without renal vein involvement or capsular extension. A CT of the chest corroborated no definite metastasis to other organs or lymph nodes. Because there was no evidence of distant metastatic disease on imaging, a right radical nephrectomy with adrenalectomy was performed by urology, without complications. The pathology report was notable for clear cell renal carcinoma. Because the patient came from a rural area, the examinations took place at a centre 3 hours away from his place of residence. The patient was subsequently examined by medical oncology, which calculated the probability of early disease progression to be low, with a recurrence rate of 8.4%. Given the low risk for recurrence, no adjuvant systemic therapy was recommended. The patient continued follow-up with medical oncology and remained under surveillance with CT scans every few months. Findings and Diagnosis At 24 months, a new right upper lobe (RUL) pulmonary nodule measuring 6 mm was found on chest CT. The nodule size was considered nonpathologic. Furthermore, the lesion was not feasible for biopsy, and the patient continued to be under close surveillance. By month 36, the RUL pulmonary nodule measured 10 mm. A new left upper lobe nodule measuring 6 mm and a new right lower lobe lesion measuring 2 mm were discovered. A follow-up PET scan showed nonavid nodules, and biopsy was not feasible. At 48 months, lesion progression prompted biopsy, which confirmed metastatic recurrence of renal cell carcinoma (RCC). The cancer was staged as IV (pT2cN0cM1). First-line treatment with nivolumab and cabozantinib was initiated. Cycles 2-5: The patient experienced mild fatigue, a grade 1 skin rash, gastrointestinal symptoms, and a 4 kg weight loss. Cycle 9: Weight loss exceeding 10% of body weight prompted cabozantinib dose reduction. Cycle 13: The patient developed diffuse skin changes, including blisters and open lesions, which led to cabozantinib discontinuation. Cycle 14: Despite stopping the TKI, he developed severe blistering skin reactions involving more than 30% of the body surface area. ICI therapy was paused, and high-dose corticosteroids were initiated. Skin biopsy confirmed BP, a rare autoimmune blistering disorder. The patient was treated with systemic corticosteroids, high-potency topical steroids, and doxycycline. Due to the limited response, rituximab was introduced for corticosteroid-refractory disease. After four doses, marked clinical improvement was observed: The skin lesions regressed, and no new blisters developed. By day 172, the patient was free of skin symptoms. Given the absence of active disease and the severity of prior toxicity, a surveillance protocol was adopted. Discussion BP is a rare but potentially life-threatening immune-related adverse event (irAE) associated with ICI therapy. Early recognition and prompt, aggressive management, including biologic agents such as rituximab, are essential to ensure optimal outcomes. The combination of ICI with TKI has become the standard therapeutic approach for the initial management of advanced RCC due to decreased mortality and increased long-term survival rates. Although this combination of medications has positively affected RCC treatment, the side effects can be severe. In this case report, it was initially suspected that cabozantinib caused cutaneous manifestations and gastrointestinal adverse effects. In numerous studies, more than 70% of patients taking cabozantinib developed one or more cutaneous toxicities, including erythema, hand-foot skin reactions with or without blisters, pruritus, seborrheic dermatitis, stomatitis, and xerosis. Alternatively, cutaneous manifestations with nivolumab have been reported in approximately 34% of patients or fewer and include maculopapular rash, eczema, lichenoid rashes, vitiligo, pruritus, and rarely, bullous eruptions. Although the dose of cabozantinib was initially reduced and eventually stopped due to multiple suspected toxicities, the patient developed a new, rapidly progressing corticosteroid-refractory rash that continued to worsen to grade 4 toxicities. The pathology was characteristic of extremely rare BP ICI toxicity. Consequently, the decision to discontinue nivolumab therapy was made. Despite discontinuation of the offending agent, his BP began to improve only after the initiation of rituximab in combination with corticosteroids. This suggests that the cutaneous toxicity was attributable to nivolumab, indicating that it was an ICI-related adverse effect. The mechanisms underlying irAEs are not fully understood. Multiple theories have been proposed, including a pro-inflammatory state, uncontrolled activity of T cells, enhanced immune activation and response, and cytokine release. Skin irAEs are the most common, encompassing 17%-40% of toxicities. This case highlights the complex care challenges faced by rural patients with cancer. The patient resided more than 3 hours from the nearest specialised oncology centre, an access barrier further compounded by the COVID-19 pandemic. With less than 7% of oncologists available in rural areas, there is a significant gap in care. The patient was able to receive cancer treatment, undergo detailed toxicity monitoring, and benefit from multidisciplinary input without a significant travel burden. Early detection and management of high-grade toxicities through remote assessments and coordinated care enabled successful treatment outcomes. Given this, structured telehealth surveillance protocols are crucial and can effectively serve rural areas that lack specialty centres.
CNN
3 hours ago
- CNN
Controversial FDA official Dr. Vinay Prasad departs agency
Dr. Vinay Prasad, the controversial critic of the US Food and Drug Administration who took a top role at the regulatory agency in May, has resigned less than three months into the job. 'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' a spokesperson for the US Department of Health and Human Services told CNN on Tuesday. Prasad, a hematologist oncologist, was named head of the FDA's Center for Biologics Evaluation and Research in early May, giving him purview over vaccines and biologic medicines. He was subsequently also given the role of FDA chief medical and scientific officer. Like a number of Trump administration health appointees, Prasad had been a harsh critic of the government's response and vaccine policies during the Covid-19 pandemic. Prasad's departure came amid fresh pressure from the White House for him to resign, according to a person familiar with the matter who was granted anonymity to describe the internal dynamics, and followed days of criticism from Laura Loomer, a right-wing activist with extraordinary access to President Donald Trump. Loomer had taken shots at him on her website and on social media, attacking him publicly for days as a 'progressive leftist saboteur' who was 'undermining President Trump's FDA.' Loomer focused on Prasad's previous social media posts and podcast episodes, where she said he aligned himself politically with liberal politicians and expressed 'disdain' for Trump. Her posts were followed by others from figures including former US Sen. Rick Santorum, who called Prasad 'the man destroying @POTUS legacy for helping patients,' and a Wall Street Journal opinion piece headlined, 'Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag.' Prasad didn't respond to requests for comment. A White House spokesperson referred a request for comment to HHS. Prasad had been defended by FDA Commissioner Dr. Marty Makary just days ago; in an interview with Politico, Makary said Prasad is an 'impeccable scientist … one of the greatest scientific minds of our generation.' 'We thank him for his service and the many important reforms he was able to achieve in his time at FDA,' the spokesperson for HHS said. Prasad assumed his role at the FDA after years of being a vocal critic of some of the agency's drug approvals. In particular, he had railed against a decision to approve Sarepta's drug for Duchenne muscular dystrophy, Elevidys, arguing that there was little evidence it helped stall or reverse symptoms of the rare, fatal genetic disorder. This month, the FDA requested that Sarepta halt shipments of the drug after a reported death in a young patient in Brazil. Just one day before Prasad's departure, the agency made a surprising reversal and allowed Sarepta to resume shipments for certain patients. Prasad also drew criticism from former officials and vaccine experts after internal memos from May revealed that he overrode FDA scientists on recommendations for two new versions of Covid-19 vaccines. The then-CDER director rebuked recommendations for broad use of the shots; the FDA eventually approved the vaccines for use in older and immunocompromised people but did not advise them for younger Americans who don't have underlying conditions.
CNN
3 hours ago
- CNN
Controversial FDA official Dr. Vinay Prasad departs agency
Dr. Vinay Prasad, the controversial critic of the US Food and Drug Administration who took a top role at the regulatory agency in May, has resigned less than three months into the job. 'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' a spokesperson for the US Department of Health and Human Services told CNN on Tuesday. Prasad, a hematologist oncologist, was named head of the FDA's Center for Biologics Evaluation and Research in early May, giving him purview over vaccines and biologic medicines. He was subsequently also given the role of FDA chief medical and scientific officer. Like a number of Trump administration health appointees, Prasad had been a harsh critic of the government's response and vaccine policies during the Covid-19 pandemic. Prasad's departure came amid fresh pressure from the White House for him to resign, according to a person familiar with the matter who was granted anonymity to describe the internal dynamics, and followed days of criticism from Laura Loomer, a right-wing activist with extraordinary access to President Donald Trump. Loomer had taken shots at him on her website and on social media, attacking him publicly for days as a 'progressive leftist saboteur' who was 'undermining President Trump's FDA.' Loomer focused on Prasad's previous social media posts and podcast episodes, where she said he aligned himself politically with liberal politicians and expressed 'disdain' for Trump. Her posts were followed by others from figures including former US Sen. Rick Santorum, who called Prasad 'the man destroying @POTUS legacy for helping patients,' and a Wall Street Journal opinion piece headlined, 'Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag.' Prasad didn't respond to requests for comment. A White House spokesperson referred a request for comment to HHS. Prasad had been defended by FDA Commissioner Dr. Marty Makary just days ago; in an interview with Politico, Makary said Prasad is an 'impeccable scientist … one of the greatest scientific minds of our generation.' 'We thank him for his service and the many important reforms he was able to achieve in his time at FDA,' the spokesperson for HHS said. Prasad assumed his role at the FDA after years of being a vocal critic of some of the agency's drug approvals. In particular, he had railed against a decision to approve Sarepta's drug for Duchenne muscular dystrophy, Elevidys, arguing that there was little evidence it helped stall or reverse symptoms of the rare, fatal genetic disorder. This month, the FDA requested that Sarepta halt shipments of the drug after a reported death in a young patient in Brazil. Just one day before Prasad's departure, the agency made a surprising reversal and allowed Sarepta to resume shipments for certain patients. Prasad also drew criticism from former officials and vaccine experts after internal memos from May revealed that he overrode FDA scientists on recommendations for two new versions of Covid-19 vaccines. The then-CDER director rebuked recommendations for broad use of the shots; the FDA eventually approved the vaccines for use in older and immunocompromised people but did not advise them for younger Americans who don't have underlying conditions.
